

# Copy of MD7512 Clinical Presentation & Management of Diabetes: Complications & Cardiovascular Disease

View Online



Clinical Presentation & Management of Diabetes:  
Complications & Cardiovascular Disease

---

[1]

Abdul-Ghani, M. et al. 2017. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? *Diabetes Care*. 40, 7 (Jul. 2017), 813–820. DOI:<https://doi.org/10.2337/dc16-2736>.

[2]

Adamsson Eryd, S. et al. 2017. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. *Diabetic Medicine*. 34, 3 (Mar. 2017), 411–418. DOI:<https://doi.org/10.1111/dme.13266>.

[3]

Andersson, D.P. et al. 2017. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. *Heart*. (Mar. 2017). DOI:<https://doi.org/10.1136/heartjnl-2016-310746>.

[4]

Atkinson, M.A. et al. 2014. Type 1 diabetes. *The Lancet*. 383, 9911 (Jan. 2014), 69–82. DOI:[https://doi.org/10.1016/S0140-6736\(13\)60591-7](https://doi.org/10.1016/S0140-6736(13)60591-7).

[5]

Azmi, S. et al. 2017. Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. *Diabetologia*. (Mar. 2017). DOI:<https://doi.org/10.1007/s00125-017-4245-z>.

[6]

Bangalore, S. et al. 2011. Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials. *Circulation*. 123, 24 (Jun. 2011), 2799–2810. DOI:<https://doi.org/10.1161/CIRCULATIONAHA.110.016337>.

[7]

Barzilay, J.I. et al. 2012. Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. *Circulation: Cardiovascular Quality and Outcomes*. 5, 2 (Mar. 2012), 153–162. DOI:<https://doi.org/10.1161/CIRCOUTCOMES.111.962522>.

[8]

Bianchi, C. et al. 2013. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? *Current Diabetes Reports*. 13, 3 (Jun. 2013), 403–410. DOI:<https://doi.org/10.1007/s11892-013-0371-2>.

[9]

Bianchi, C. et al. 2013. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? *Current Diabetes Reports*. 13, 3 (Jun. 2013), 403–410. DOI:<https://doi.org/10.1007/s11892-013-0371-2>.

[10]

Black, J.A. et al. 2014. Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. *British Journal of General Practice*. 64, 621 (Apr. 2014), e208–e216. DOI:<https://doi.org/10.3399/bjgp14X677833>.

[11]

Boulton, A.J. et al. 2009. International collaborative research on Charcot's disease - 2009. *The Lancet*. 373, 9658 (Jan. 2009), 105–106. DOI:[https://doi.org/10.1016/S0140-6736\(09\)60019-2](https://doi.org/10.1016/S0140-6736(09)60019-2).

[12]

Boussageon, R. et al. 2011. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. *BMJ*. 343, jul26 1 (Jul. 2011), d4169–d4169. DOI:<https://doi.org/10.1136/bmj.d4169>.

[13]

Braffett, B.H. et al. 2016. Urogenital Autonomic Dysfunction in Diabetes. *Current Diabetes Reports*. 16, 12 (Dec. 2016). DOI:<https://doi.org/10.1007/s11892-016-0824-5>.

[14]

Çakici, N. et al. 2016. Systematic review of treatments for diabetic peripheral neuropathy. *Diabetic Medicine*. 33, 11 (Nov. 2016), 1466–1476. DOI:<https://doi.org/10.1111/dme.13083>.

[15]

Çakici, N. et al. 2016. Systematic review of treatments for diabetic peripheral neuropathy. *Diabetic Medicine*. 33, 11 (Nov. 2016), 1466–1476. DOI:<https://doi.org/10.1111/dme.13083>.

[16]

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes - ClinicalKey:  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947>.

[17]

Cefalu, W.T. et al. 2016. Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory". *Diabetes Care*. 39, 5 (May 2016), 664–667. DOI:<https://doi.org/10.2337/dc16-0405>.

[18]

Chatterjee, S. et al. 2017. Type 2 diabetes. *The Lancet*. (Feb. 2017). DOI:[https://doi.org/10.1016/S0140-6736\(17\)30058-2](https://doi.org/10.1016/S0140-6736(17)30058-2).

[19]

Cheung, N. et al. 2010. Diabetic retinopathy. *The Lancet*. 376, 9735 (Jul. 2010), 124–136. DOI:[https://doi.org/10.1016/S0140-6736\(09\)62124-3](https://doi.org/10.1016/S0140-6736(09)62124-3).

[20]

Chloe L. Edridge 2015. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. *PLoS ONE*. 10, 6 (2015). DOI:<https://doi.org/doi:10.1371/journal.pone.0126427>.

[21]

Clokie, M. et al. 2017. New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium. *Diabetic Medicine*. 34, 3 (Mar. 2017), 305–315. DOI:<https://doi.org/10.1111/dme.13313>.

[22]

Dahlöf, B. et al. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *The Lancet*. 366, 9489 (Sep. 2005), 895–906. DOI:[https://doi.org/10.1016/S0140-6736\(05\)67185-1](https://doi.org/10.1016/S0140-6736(05)67185-1).

[23]

Dana Dabelea Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. *JAMA*. 317, 8, 825–835. DOI:<https://doi.org/10.1001/jama.2017.0686>.

[24]

Denig, P. et al. 2014. Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. *BMJ*. 349, sep25 6 (Sep. 2014), g5651–g5651. DOI:<https://doi.org/10.1136/bmj.g5651>.

[25]

Dhatariya, K. et al. 2012. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. *Diabetic Medicine*. 29, 4 (Apr. 2012), 420–433.  
DOI:<https://doi.org/10.1111/j.1464-5491.2012.03582.x>.

[26]

Dhatariya, K.K. and Vellanki, P. 2017. Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). *Current Diabetes Reports*. 17, 5 (May 2017).  
DOI:<https://doi.org/10.1007/s11892-017-0857-4>.

[27]

Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey:  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>.

[28]

Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey:  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>.

[29]

Duckworth, W. et al. 2009. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. *New England Journal of Medicine*. 360, 2 (Jan. 2009), 129–139.  
DOI:<https://doi.org/10.1056/NEJMoa0808431>.

[30]

Dwamena, F. et al. 1996. Interventions for providers to promote a patient-centred approach in clinical consultations. *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd.

[31]

Ele Ferrannini 2015. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. *European Heart Journal*. 36, 34 (2015), 2288-2296.

[32]

Elliott, W.J. and Meyer, P.M. 2007. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *The Lancet*. 369, 9557 (Jan. 2007), 201-207.  
DOI:[https://doi.org/10.1016/S0140-6736\(07\)60108-1](https://doi.org/10.1016/S0140-6736(07)60108-1).

[33]

Ferrannini, E. and Cushman, W.C. 2012. Diabetes and hypertension: the bad companions. *The Lancet*. 380, 9841 (Aug. 2012), 601-610.  
DOI:[https://doi.org/10.1016/S0140-6736\(12\)60987-8](https://doi.org/10.1016/S0140-6736(12)60987-8).

[34]

Filippatos, T. et al. 2017. Pathophysiology of diabetic dyslipidaemia. *Current Vascular Pharmacology*. 15, 999 (Feb. 2017), 1-1.

[35]

Fisher, L. et al. 2014. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. *Diabetic Medicine*. 31, 7 (Jul. 2014), 764-772. DOI:<https://doi.org/10.1111/dme.12428>.

[36]

Foresta, C. et al. 2017. The great opportunity of the andrological patient: cardiovascular and metabolic risk assessment and prevention. *Andrology*. (Mar. 2017).  
DOI:<https://doi.org/10.1111/andr.12342>.

[37]

Fox, C.S. et al. 2015. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. *Diabetes Care*. 38, 9 (Sep.

2015), 1777–1803. DOI:<https://doi.org/10.2337/dci15-0012>.

[38]

Gæde, P. et al. 2008. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. *New England Journal of Medicine*. 358, 6 (Feb. 2008), 580–591. DOI:<https://doi.org/10.1056/NEJMoa0706245>.

[39]

Gæde, P. et al. 2016. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. *Diabetologia*. 59, 11 (Nov. 2016), 2298–2307. DOI:<https://doi.org/10.1007/s00125-016-4065-6>.

[40]

Game, F. 2016. Classification of diabetic foot ulcers. *Diabetes/Metabolism Research and Reviews*. 32, (Jan. 2016), 186–194. DOI:<https://doi.org/10.1002/dmrr.2746>.

[41]

Giorgino, F. et al. 2016. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? *Diabetes Care*. 39, Supplement 2 (Aug. 2016), S187–S195. DOI:<https://doi.org/10.2337/dcS15-3023>.

[42]

Giovanni Corona 2016. Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. *PLoS ONE*. 11, 10 (2016). DOI:<https://doi.org/doi:10.1371/journal.pone.0157915>.

[43]

Hayward, R.A. et al. 2015. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 372, 23 (Jun. 2015), 2197–2206. DOI:<https://doi.org/10.1056/NEJMoa1414266>.

[44]

Hayward, R.A. et al. 2015. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 372, 23 (Jun. 2015), 2197–2206. DOI:<https://doi.org/10.1056/NEJMoa1414266>.

[45]

Holman, R.R. et al. 2008. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. *New England Journal of Medicine*. 359, 15 (Oct. 2008), 1577–1589. DOI:<https://doi.org/10.1056/NEJMoa0806470>.

[46]

Holman, R.R. et al. 2017. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 377, 13 (Sep. 2017), 1228–1239. DOI:<https://doi.org/10.1056/NEJMoa1612917>.

[47]

Holt, R.I.G. et al. 2016. *Textbook of Diabetes*. John Wiley & Sons, Incorporated.

[48]

Holt, R.I.G. 2010. *Textbook of diabetes*. Wiley-Blackwell.

[49]

Holt, R.I.G. et al. eds. 2017. *Textbook of diabetes*. Wiley Blackwell.

[50]

Holt, R.I.G. 2017. Understanding of the causes and management of diabetic foot disease. *Diabetic Medicine*. 34, 3 (Mar. 2017), 303–304. DOI:<https://doi.org/10.1111/dme.13319>.

[51]

Hotaling, J.M. et al. 2016. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and



Urinary Incontinence in Women With Type 1 Diabetes. *Diabetes Care*. 39, 9 (Sep. 2016), 1587–1593. DOI:<https://doi.org/10.2337/dc16-0059>.

[52]

Hotaling, J.M. et al. 2016. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. *Diabetes Care*. 39, 9 (Sep. 2016), 1587–1593. DOI:<https://doi.org/10.2337/dc16-0059>.

[53]

Hypertension: Clinical Management of Primary Hypertension in Adults | NICE guideline 127. August 2011: <http://www.nice.org.uk/guidance/cg127>.

[54]

Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, , Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. *Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges*.

[55]

Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials- ClinicalKey:  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998>.

[56]

Jhamb, S. et al. 2016. Genetic and molecular basis of diabetic foot ulcers: Clinical review. *Journal of Tissue Viability*. 25, 4 (Nov. 2016), 229–236. DOI:<https://doi.org/10.1016/j.jtv.2016.06.005>.

[57]

Jin, D. et al. 2010. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials. *Diabetes Research and Clinical Practice*. 89, 1 (Jul. 2010), 10–15.

DOI:<https://doi.org/10.1016/j.diabres.2010.03.021>.

[58]

Johal, S. et al. 2017. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. *Diabetic Medicine*. (Jun. 2017). DOI:<https://doi.org/10.1111/dme.13383>.

[59]

Kaul, S. 2017. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. *Diabetes Care*. 40, 7 (Jul. 2017), 821–831. DOI:<https://doi.org/10.2337/dc17-0291>.

[60]

Khunti, K. et al. 2013. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. *Diabetes Care*. 36, 11 (Nov. 2013), 3411–3417. DOI:<https://doi.org/10.2337/dc13-0331>.

[61]

Khunti, K. et al. 2015. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care*. 38, 2 (Feb. 2015), 316–322. DOI:<https://doi.org/10.2337/dc14-0920>.

[62]

Khunti, K. et al. 2015. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care*. 38, 2 (Feb. 2015), 316–322. DOI:<https://doi.org/10.2337/dc14-0920>.

[63]

Koye, D.N. et al. 2017. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. *Diabetic Medicine*. (Feb. 2017). DOI:<https://doi.org/10.1111/dme.13324>.

[64]

Kunutsor, S.K. et al. 2017. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. *Diabetic Medicine*. 34, 3 (Mar. 2017), 316–327. DOI:<https://doi.org/10.1111/dme.13133>.

[65]

Liew, G. et al. 2009. Systemic management of diabetic retinopathy. *BMJ*. 338, feb12 1 (Feb. 2009), b441–b441. DOI:<https://doi.org/10.1136/bmj.b441>.

[66]

Lindholm, L.H. et al. 2002. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *The Lancet*. 359, 9311 (Mar. 2002), 1004–1010. DOI:[https://doi.org/10.1016/S0140-6736\(02\)08090-X](https://doi.org/10.1016/S0140-6736(02)08090-X).

[67]

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - ClinicalKey:  
<https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036>.

[68]

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey:  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>.

[69]

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey:  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>.

[70]

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey:  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>.

[71]

Malavige, L.S. et al. 2015. The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study. *European Journal of Medical Research*. 20, 1 (Dec. 2015). DOI:<https://doi.org/10.1186/s40001-015-0186-5>.

[72]

Marso, S.P. et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 375, 4 (Jul. 2016), 311-322.  
DOI:<https://doi.org/10.1056/NEJMoa1603827>.

[73]

Matheus, A.S. de M. et al. 2013. Impact of Diabetes on Cardiovascular Disease: An Update. *International Journal of Hypertension*. 2013, (2013), 1-15.  
DOI:<https://doi.org/10.1155/2013/653789>.

[74]

Mayer-Davis, E.J. et al. 2017. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. *New England Journal of Medicine*. 376, 15 (Apr. 2017), 1419-1429.  
DOI:<https://doi.org/10.1056/NEJMoa1610187>.

[75]

Melanie Davies 2016. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. *Clinical Pharmacology : Advances and Applications*. 8, (2016). DOI:<https://doi.org/doi:10.2147/CPAA.S82008>.

[76]

Micha, R. et al. 2017. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. *JAMA*. 317, 9 (Mar. 2017). DOI:<https://doi.org/10.1001/jama.2017.0947>.

[77]

Miller, M.E. et al. 2010. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. *BMJ*. 340, jan08 1 (Jan. 2010), b5444-b5444. DOI:<https://doi.org/10.1136/bmj.b5444>.

[78]

Moreton, R.B.R. et al. 2017. Factors determining uptake of diabetic retinopathy screening in Oxfordshire. *Diabetic Medicine*. 34, 7 (Jul. 2017), 993-999. DOI:<https://doi.org/10.1111/dme.13350>.

[79]

Navaneethan, S.D. et al. 2017. Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. *American Journal of Kidney Diseases*. (Feb. 2017). DOI:<https://doi.org/10.1053/j.ajkd.2016.11.018>.

[80]

Nicolucci, A. and Standl, E. 2011. Antiplatelet Therapy for Every Diabetic Person? *Diabetes Care*. 34, Supplement\_2 (May 2011), S150-S154. DOI:<https://doi.org/10.2337/dc11-s210>.

[81]

Older antidiabetic drugs | *The British Journal of Cardiology*:  
<https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/>.

[82]

Omland, T. et al. 2016. Relation of Erectile Dysfunction to Subclinical Myocardial Injury. *The American Journal of Cardiology*. 118, 12 (Dec. 2016), 1821-1825. DOI:<https://doi.org/10.1016/j.amjcard.2016.08.070>.

[83]

Orchard, T.J. et al. 2015. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. *JAMA*. 313, 1 (Jan. 2015). DOI:<https://doi.org/10.1001/jama.2014.16107>.

[84]

P Naidoo 2015. Lower limb complications of diabetes mellitus: a comprehensive review with clinicopathological insights from a dedicated high-risk diabetic foot multidisciplinary team. *The British Journal of Radiology*. 88, 1053 (2015). DOI:<https://doi.org/doi:10.1259/bjr.20150135>.

[85]

Paul, S.K. et al. 2015. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. *Cardiovascular Diabetology*. 14, 1 (Dec. 2015). DOI:<https://doi.org/10.1186/s12933-015-0260-x>.

[86]

Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey:  
<https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020>.

[87]

Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey:  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020>.

[88]

Personalised treatment targets in type 2 diabetes patients: The Dutch approach - ClinicalKey:  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626>.

[89]

Pickering, R.J. et al. 2018. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. *Clinical & Translational Immunology*. 7, 4 (2018). DOI:<https://doi.org/10.1002/cti2.1016>.

[90]

Piepoli, M.F. et al. 2016. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Atherosclerosis*. 252, (Sep. 2016), 207–274. DOI:<https://doi.org/10.1016/j.atherosclerosis.2016.05.037>.

[91]

Proceedings of the 5th International DAWN Summit 2014: Acting together to make person-centred diabetes care a reality - ClinicalKey:  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862>.

[92]

Rawshani, A. et al. 2017. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine*. 376, 15 (Apr. 2017), 1407–1418. DOI:<https://doi.org/10.1056/NEJMoa1608664>.

[93]

Rawshani, A. et al. 2017. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine*. 376, 15 (Apr. 2017), 1407–1418. DOI:<https://doi.org/10.1056/NEJMoa1608664>.

[94]

Ray, K.K. et al. 2009. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *The Lancet*. 373, 9677 (May 2009), 1765–1772. DOI:[https://doi.org/10.1016/S0140-6736\(09\)60697-8](https://doi.org/10.1016/S0140-6736(09)60697-8).

[95]

Richard W. Nesto 2008. LDL cholesterol lowering in type 2 diabetes: what is the optimum approach? *Clinical Diabetes*. 26, 1 (2008).

[96]

Ritholz, M.D. et al. 2017. Difficult conversations: adults with diabetes and the discussion of microvascular complications. *Diabetic Medicine*. (Jul. 2017). DOI:<https://doi.org/10.1111/dme.13419>.

[97]

Ritholz, M.D. et al. 2017. Difficult conversations: adults with diabetes and the discussion of microvascular complications. *Diabetic Medicine*. 34, 10 (Oct. 2017), 1447–1455. DOI:<https://doi.org/10.1111/dme.13419>.

[98]

Romero-Aroca, P. et al. 2017. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology*. (Mar. 2017). DOI:<https://doi.org/10.1136/bjophthalmol-2016-310063>.

[99]

Romero-Aroca, P. et al. 2017. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology*. (Mar. 2017). DOI:<https://doi.org/10.1136/bjophthalmol-2016-310063>.

[100]

Romero-Aroca, P. et al. 2017. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology*. (Mar. 2017). DOI:<https://doi.org/10.1136/bjophthalmol-2016-310063>.

[101]

Rosenberg, J.B. and Tsui, I. 2017. Screening for Diabetic Retinopathy. *New England Journal of Medicine*. 376, 16 (Apr. 2017), 1587–1588. DOI:<https://doi.org/10.1056/NEJMe1701820>.



[102]

Saha, S.A. and Arora, R.R. 2010. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. *International Journal of Cardiology*. 141, 2 (May 2010), 157–166. DOI:<https://doi.org/10.1016/j.ijcard.2008.11.211>.

[103]

Santi, D. et al. 2016. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. *European Journal of Endocrinology*. 174, 4 (Apr. 2016), 513–522. DOI:<https://doi.org/10.1530/EJE-15-1100>.

[104]

Schrier, R.W. et al. 1996. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. *Diabetologia*. 39, 12 (Nov. 1996), 1646–1654. DOI:<https://doi.org/10.1007/s001250050629>.

[105]

Scott, A.R. 2015. Management of hyperosmolar hyperglycaemic state in adults with diabetes. *Diabetic Medicine*. 32, 6 (Jun. 2015), 714–724. DOI:<https://doi.org/10.1111/dme.12757>.

[106]

Seidu, S. et al. 2016. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. *Diabetic Medicine*. 33, 3 (Mar. 2016), 280–289. DOI:<https://doi.org/10.1111/dme.12885>.

[107]

Soliman, E.Z. et al. 2017. Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. *Diabetes Care*. 40, 6 (Jun. 2017), 793–799. DOI:<https://doi.org/10.2337/dc16-2050>.

[108]

Solomon, S.D. et al. 2017. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care*. 40, 3 (Mar. 2017), 412–418.  
DOI:<https://doi.org/10.2337/dc16-2641>.

[109]

Solomon, S.D. et al. 2017. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412–418. *Diabetes Care*. 40, 6 (Jun. 2017), 809.3-809. DOI:<https://doi.org/10.2337/dc17-er06e>.

[110]

Solomon, S.D. et al. 2017. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412–418. *Diabetes Care*. (Apr. 2017). DOI:<https://doi.org/10.2337/dc17-er06e>.

[111]

Solomon, S.D. et al. 2017. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412–418. *Diabetes Care*. (Apr. 2017). DOI:<https://doi.org/10.2337/dc17-er06e>.

[112]

Sultan, A. et al. 2017. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. *Diabetic Medicine*. (Apr. 2017).  
DOI:<https://doi.org/10.1111/dme.13364>.

[113]

Sultan, A. et al. 2017. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. *Diabetic Medicine*. (Apr. 2017).  
DOI:<https://doi.org/10.1111/dme.13364>.

[114]

The changing face of diabetes complications - ClinicalKey:

<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109>.

[115]

The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management - ClinicalKey:

<https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728>.

[116]

The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check:

[http://www.healthcheck.nhs.uk/news/the\\_handbook\\_for\\_vascular\\_risk\\_assessment\\_risk\\_reduction\\_and\\_risk\\_management/](http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/).

[117]

Turnbull, F.M. et al. 2009. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia*. 52, 11 (Nov. 2009), 2288-2298.

DOI:<https://doi.org/10.1007/s00125-009-1470-0>.

[118]

Turnbull, F.M. et al. 2009. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia*. 52, 11 (Nov. 2009), 2288-2298.

DOI:<https://doi.org/10.1007/s00125-009-1470-0>.

[119]

UK Prospective Diabetes Study Group 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ: British Medical Journal*. 317, 7160 (1998).

[120]

Umpierrez, G. and Korytkowski, M. 2016. Diabetic emergencies — ketoacidosis,

hyperglycaemic hyperosmolar state and hypoglycaemia. *Nature Reviews Endocrinology*. 12, 4 (Feb. 2016), 222–232. DOI:<https://doi.org/10.1038/nrendo.2016.15>.

[121]

Umpierrez, G. and Korytkowski, M. 2016. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. *Nature Reviews Endocrinology*. 12, 4 (Feb. 2016), 222–232. DOI:<https://doi.org/10.1038/nrendo.2016.15>.

[122]

Valencia, W.M. and Florez, H. 2017. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. *BMJ*. (Jan. 2017). DOI:<https://doi.org/10.1136/bmj.i6505>.

[123]

Wannamethee, S.G. et al. 2011. Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: influence of age at onset, diabetes duration and established and novel risk factors. *Archives of Internal Medicine*. 171, 5 (Mar. 2011). DOI:<https://doi.org/10.1001/archinternmed.2011.2>.

[124]

Webb, D.R. et al. 2016. Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. *Diabetes/Metabolism Research and Reviews*. (2016). DOI:<https://doi.org/10.1002/dmrr.2877>.

[125]

Weber, M.A. et al. 2010. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. *Journal of the American College of Cardiology*. 56, 1 (Jun. 2010), 77–85. DOI:<https://doi.org/10.1016/j.jacc.2010.02.046>.

[126]

Whelton, P.K. 2005. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. *Archives of Internal Medicine*. 165, 12 (Jun. 2005). DOI:<https://doi.org/10.1001/archinte.165.12.1401>.

[127]

White, J. et al. 2016. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. *JAMA Cardiology*. 1, 6 (Sep. 2016).  
DOI:<https://doi.org/10.1001/jamacardio.2016.1884>.

[128]

Wong, M.G. et al. 2016. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care*. 39, 5 (May 2016), 694–700.  
DOI:<https://doi.org/10.2337/dc15-2322>.

[129]

Wong, M.G. et al. 2016. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care*. 39, 5 (May 2016), 694–700.  
DOI:<https://doi.org/10.2337/dc15-2322>.

[130]

Yavuz, M. et al. 2017. Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration. *Diabetes Care*. 40, 2 (Feb. 2017), e14–e15. DOI:<https://doi.org/10.2337/dc16-2204>.

[131]

Yudkin, J.S. et al. 2011. Intensified glucose control in type 2 diabetes—whose agenda? *The Lancet*. 377, 9773 (Apr. 2011), 1220–1222.  
DOI:[https://doi.org/10.1016/S0140-6736\(10\)61112-9](https://doi.org/10.1016/S0140-6736(10)61112-9).

[132]

Zaccardi, F. et al. 2017. Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation. *Diabetologia*. (Mar. 2017). DOI:<https://doi.org/10.1007/s00125-017-4235-1>.

[133]

Zaccardi, F. et al. 2017. Risk factors and outcome differences in hypoglycaemia-related hospital admissions: A case-control study in England. *Diabetes, Obesity and Metabolism*. (Apr. 2017). DOI:<https://doi.org/10.1111/dom.12941>.

[134]

Zhang, C.-Y. et al. 2010. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. *Annals of Medicine*. 42, 4 (May 2010), 305–315. DOI:<https://doi.org/10.3109/07853891003796752>.

[135]

Zinman, B. et al. 2015. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New England Journal of Medicine*. 373, 22 (Nov. 2015), 2117–2128. DOI:<https://doi.org/10.1056/NEJMoa1504720>.

[136]

Zoungas, S. et al. 2017. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *The Lancet Diabetes & Endocrinology*. 5, 6 (Jun. 2017), 431–437. DOI:[https://doi.org/10.1016/S2213-8587\(17\)30104-3](https://doi.org/10.1016/S2213-8587(17)30104-3).

[137]

Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. Prime.

[138]

2010. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *The Lancet*. 375, 9733 (Jun. 2010), 2215–2222. DOI:[https://doi.org/10.1016/S0140-6736\(10\)60484-9](https://doi.org/10.1016/S0140-6736(10)60484-9).

[139]

2011. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. *New England Journal of Medicine*. 364, 9 (Mar. 2011), 829–841. DOI:<https://doi.org/10.1056/NEJMoa1008862>.

[140]

Diabetic foot problems: prevention and management | Guidance and guidelines | NICE.

[141]

1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *The Lancet*. 352, 9131 (Sep. 1998), 854–865. DOI:[https://doi.org/10.1016/S0140-6736\(98\)07037-8](https://doi.org/10.1016/S0140-6736(98)07037-8).

[142]

2010. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 362, 17 (Apr. 2010), 1563–1574. DOI:<https://doi.org/10.1056/NEJMoa1001282>.

[143]

2005. Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. *Archives of Internal Medicine*. 165, 12 (Jun. 2005). DOI:<https://doi.org/10.1001/archinte.165.12.1410>.

[144]

2010. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 362, 17 (Apr. 2010), 1575–1585. DOI:<https://doi.org/10.1056/NEJMoa1001286>.

[145]

2010. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 362, 17 (Apr. 2010), 1575–1585. DOI:<https://doi.org/10.1056/NEJMoa1001286>.

[146]

2008. Effects of Intensive Glucose Lowering in Type 2 Diabetes. *New England Journal of Medicine*. 358, 24 (Jun. 2008), 2545–2559. DOI:<https://doi.org/10.1056/NEJMoa0802743>.

[147]

Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME - ClinicalKey.

[148]

2017. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. *New England Journal of Medicine*. 376, 16 (Apr. 2017), 1507–1516. DOI:<https://doi.org/10.1056/NEJMoa1612836>.

[149]

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes - ClinicalKey.

[150]

2008. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 358, 24 (Jun. 2008), 2560–2572. DOI:<https://doi.org/10.1056/NEJMoa0802987>.

[151]

2005. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. *New England Journal of Medicine*. 353, 25 (Dec. 2005), 2643–2653. DOI:<https://doi.org/10.1056/NEJMoa052187>.

[152]

2015. *International Textbook of Diabetes Mellitus*. John Wiley & Sons, Incorporated.

[153]



2011. Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. *New England Journal of Medicine*. 364, 9 (Mar. 2011), 818–828.  
DOI:<https://doi.org/10.1056/NEJMoa1006524>.

[154]

2017. Microvascular Complications and Foot Care. *Diabetes Care*. 40, Supplement 1 (Jan. 2017), S88–S98. DOI:<https://doi.org/10.2337/dc17-S013>.

[155]

2015. Minimizing Hypoglycemia in Diabetes: Table 1. *Diabetes Care*. 38, 8 (Aug. 2015), 1583–1591. DOI:<https://doi.org/10.2337/dc15-0279>.

[156]

2017. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine*. 377, 3 (Jul. 2017), 300–301.  
DOI:<https://doi.org/10.1056/NEJMc1706292>.

[157]

1993. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *New England Journal of Medicine*. 329, 14 (Sep. 1993), 977–986.  
DOI:<https://doi.org/10.1056/NEJM199309303291401>.

[158]

Type 1 diabetes in adults: diagnosis and management | Guidance and guidelines | NICE.

[159]

Type 2 diabetes in adults: management | Guidance and guidelines | NICE.